GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CTT Pharmaceutical Holdings CTTH · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.05

-16.61%

Close of 4 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−$155,907

FY2016FY2025

Free cash flow

−$75,470

FY2016FY2025

Shareholders' equity

$55,160

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue——————$49,204$25,000$40,000—
Gross profit−$6,432−$6,398−$6,398−$6,398——$49,204$25,000$40,000—
Operating income−$153,903−$250,000−$42,090−$109,000−$148,000−$584,000−$591,000−$1.7m−$1.4m−$640,000
Net income−$155,907−$210,000−$42,215−$53,448−$133,000−$586,000−$586,000−$1.7m−$1.4m−$643,000
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.01-0.01-0.04-0.04-0.03

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$86,158$73,042$79,326$93,864$107,698$375,828$573,155$781,448$186,539$99,624
Cash and short-term investments$15,359$114—$8,096$102,097$202,155$388,782$780,092$136,539$99,624
Total liabilities$31,018$40,859$19,291$4,614$102,422$662,601$450,384$281,351$276,119$205,488
Debt$18,814$16,933$10,880—————$58,430$54,768
Shareholders' equity$55,160$32,183$60,035$89,250$5,276−$286,773$122,771$500,097−$89,580−$105,864
Shares outstanding58m54m48m48m50m48m48m47m39m24m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$75,467−$228,320−$21,096−$138,839−$600,253−$186,222−$390,448−$299,656−$145,159−$6,059
Capital spending−$3−$1——−$3—————
Free cash flow−$75,470−$228,321−$21,096−$138,839−$600,256−$186,222−$390,448−$299,656−$145,159−$6,059

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit−$1,703−$1,703−$1,632−$1,600−$1,600−$1,600−$6,398—
Operating income−$20,897−$84,674−$14,686−$15,379−$7,274−$82,957−$5,113−$35,802
Net income−$15,234−$84,674−$50,255−$15,379−$7,274−$82,999−$6,177−$36,272
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$67,434$76,195$86,158$102,803$102,168$119,837$73,042—
Cash and short-term investments$31$7,089$15,359$30,544$32,439$48,510$114—
Debt$19,442$18,814$18,814$17,043$17,403$17,403$16,933—
Shareholders' equity$26,043$41,277$55,160$81,760$82,139$89,394$32,183—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income12.2%-23.4%-20.1%
Net income42.9%-23.3%-20.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2018
Price to earnings-22.4-8.2-3.9-0.1—
Price to sales————0.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return32%1193%2090%5938%140%-71%-61%141%12150%11858%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 28 Aug 2015
  • 20-to-1 reverse split · 26 Jul 2011
  • 3-for-2 split · 27 Sept 2004
  • 2-for-1 split · 13 Jun 2003
  • 100-to-1 reverse split · 7 Jan 2002

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.